Three-dimensional spheroid culture of human gingiva-derived mesenchymal stem cells enhances mitigation of chemotherapy-induced oral mucositis

Mesenchymal stem cells (MSCs) are capable of regenerative and immunomodulatory functions in cell-based therapies in a variety of human diseases and injuries; however, their therapeutic efficacy and potential side effects remain major obstacles in clinical applications. We report here a 3D spheroid c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stem cells and development Jg. 21; H. 6; S. 937
Hauptverfasser:	Zhang, Qunzhou, Nguyen, Andrew L, Shi, Shihong, Hill, Colin, Wilder-Smith, Petra, Krasieva, Tatiana B, Le, Anh D
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 10.04.2012
Schlagworte:	Animals Cell Culture Techniques Drug-Related Side Effects and Adverse Reactions Gingiva - pathology Mesenchymal Stem Cell Transplantation Mesenchymal Stromal Cells - cytology Mice Spheroids, Cellular - pathology Stomatitis - pathology Stomatitis - prevention & control Stomatitis - therapy Treatment Outcome
ISSN:	1557-8534, 1557-8534
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Mesenchymal stem cells (MSCs) are capable of regenerative and immunomodulatory functions in cell-based therapies in a variety of human diseases and injuries; however, their therapeutic efficacy and potential side effects remain major obstacles in clinical applications. We report here a 3D spheroid culture approach to optimize stem cell properties and therapeutic effects of human gingiva-derived mesenchymal stem cells (GMSCs) in mitigation of experimental oral mucositis. Under growth condition of ultra-low attachment, GMSCs spontaneously aggregated into 3D spheroids and exhibited distinct early stem cell phenotype characterized by elevated expression Stro-1 and CXC chemokine receptor 4 (CXCR-4) as well as OCT-4 and Nanog, 2 important transcriptional factors relevant to stem cell properties, and decreased expression of MSC-associated markers, including CD29, CD90, and CD105. Functionally, spheroid GMSCs are capable of enhanced multipotency and augmented secretion of several chemokines and cytokines relevant to cell migration, survival, and angiogenesis. More importantly, spheroid GMSCs expressed increased levels of reactive oxygen species, hypoxia-inducible factor (HIF)-1 and -2α, and manganese superoxide dismutase, which correlated with improved resistance to oxidative stress-induced apoptosis. Using an in vivo murine model of chemotherapy-induced oral mucositis, we demonstrated that spheroid-derived GMSCs possessed better therapeutic efficacy than their adherent cells in reversing body weight loss and promoting the regeneration of disrupted epithelial lining of the mucositic tongues. These findings suggest that 3D spheroid culture allows early stemness preservation and potentially precondition GMSCs for enhanced mitigation of oral mucositis.
AbstractList	Mesenchymal stem cells (MSCs) are capable of regenerative and immunomodulatory functions in cell-based therapies in a variety of human diseases and injuries; however, their therapeutic efficacy and potential side effects remain major obstacles in clinical applications. We report here a 3D spheroid culture approach to optimize stem cell properties and therapeutic effects of human gingiva-derived mesenchymal stem cells (GMSCs) in mitigation of experimental oral mucositis. Under growth condition of ultra-low attachment, GMSCs spontaneously aggregated into 3D spheroids and exhibited distinct early stem cell phenotype characterized by elevated expression Stro-1 and CXC chemokine receptor 4 (CXCR-4) as well as OCT-4 and Nanog, 2 important transcriptional factors relevant to stem cell properties, and decreased expression of MSC-associated markers, including CD29, CD90, and CD105. Functionally, spheroid GMSCs are capable of enhanced multipotency and augmented secretion of several chemokines and cytokines relevant to cell migration, survival, and angiogenesis. More importantly, spheroid GMSCs expressed increased levels of reactive oxygen species, hypoxia-inducible factor (HIF)-1 and -2α, and manganese superoxide dismutase, which correlated with improved resistance to oxidative stress-induced apoptosis. Using an in vivo murine model of chemotherapy-induced oral mucositis, we demonstrated that spheroid-derived GMSCs possessed better therapeutic efficacy than their adherent cells in reversing body weight loss and promoting the regeneration of disrupted epithelial lining of the mucositic tongues. These findings suggest that 3D spheroid culture allows early stemness preservation and potentially precondition GMSCs for enhanced mitigation of oral mucositis.Mesenchymal stem cells (MSCs) are capable of regenerative and immunomodulatory functions in cell-based therapies in a variety of human diseases and injuries; however, their therapeutic efficacy and potential side effects remain major obstacles in clinical applications. We report here a 3D spheroid culture approach to optimize stem cell properties and therapeutic effects of human gingiva-derived mesenchymal stem cells (GMSCs) in mitigation of experimental oral mucositis. Under growth condition of ultra-low attachment, GMSCs spontaneously aggregated into 3D spheroids and exhibited distinct early stem cell phenotype characterized by elevated expression Stro-1 and CXC chemokine receptor 4 (CXCR-4) as well as OCT-4 and Nanog, 2 important transcriptional factors relevant to stem cell properties, and decreased expression of MSC-associated markers, including CD29, CD90, and CD105. Functionally, spheroid GMSCs are capable of enhanced multipotency and augmented secretion of several chemokines and cytokines relevant to cell migration, survival, and angiogenesis. More importantly, spheroid GMSCs expressed increased levels of reactive oxygen species, hypoxia-inducible factor (HIF)-1 and -2α, and manganese superoxide dismutase, which correlated with improved resistance to oxidative stress-induced apoptosis. Using an in vivo murine model of chemotherapy-induced oral mucositis, we demonstrated that spheroid-derived GMSCs possessed better therapeutic efficacy than their adherent cells in reversing body weight loss and promoting the regeneration of disrupted epithelial lining of the mucositic tongues. These findings suggest that 3D spheroid culture allows early stemness preservation and potentially precondition GMSCs for enhanced mitigation of oral mucositis. Mesenchymal stem cells (MSCs) are capable of regenerative and immunomodulatory functions in cell-based therapies in a variety of human diseases and injuries; however, their therapeutic efficacy and potential side effects remain major obstacles in clinical applications. We report here a 3D spheroid culture approach to optimize stem cell properties and therapeutic effects of human gingiva-derived mesenchymal stem cells (GMSCs) in mitigation of experimental oral mucositis. Under growth condition of ultra-low attachment, GMSCs spontaneously aggregated into 3D spheroids and exhibited distinct early stem cell phenotype characterized by elevated expression Stro-1 and CXC chemokine receptor 4 (CXCR-4) as well as OCT-4 and Nanog, 2 important transcriptional factors relevant to stem cell properties, and decreased expression of MSC-associated markers, including CD29, CD90, and CD105. Functionally, spheroid GMSCs are capable of enhanced multipotency and augmented secretion of several chemokines and cytokines relevant to cell migration, survival, and angiogenesis. More importantly, spheroid GMSCs expressed increased levels of reactive oxygen species, hypoxia-inducible factor (HIF)-1 and -2α, and manganese superoxide dismutase, which correlated with improved resistance to oxidative stress-induced apoptosis. Using an in vivo murine model of chemotherapy-induced oral mucositis, we demonstrated that spheroid-derived GMSCs possessed better therapeutic efficacy than their adherent cells in reversing body weight loss and promoting the regeneration of disrupted epithelial lining of the mucositic tongues. These findings suggest that 3D spheroid culture allows early stemness preservation and potentially precondition GMSCs for enhanced mitigation of oral mucositis.
Author	Hill, Colin Nguyen, Andrew L Shi, Shihong Krasieva, Tatiana B Zhang, Qunzhou Wilder-Smith, Petra Le, Anh D
Author_xml	– sequence: 1 givenname: Qunzhou surname: Zhang fullname: Zhang, Qunzhou organization: Center for Craniofacial Molecular Biology, The Herman Ostrow School of Dentistry of University of Southern California, Los Angeles, California 90033, USA – sequence: 2 givenname: Andrew L surname: Nguyen fullname: Nguyen, Andrew L – sequence: 3 givenname: Shihong surname: Shi fullname: Shi, Shihong – sequence: 4 givenname: Colin surname: Hill fullname: Hill, Colin – sequence: 5 givenname: Petra surname: Wilder-Smith fullname: Wilder-Smith, Petra – sequence: 6 givenname: Tatiana B surname: Krasieva fullname: Krasieva, Tatiana B – sequence: 7 givenname: Anh D surname: Le fullname: Le, Anh D
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/21689066$$D View this record in MEDLINE/PubMed
BookMark	eNpNkDtPwzAUhS0Eog8YWZE3phTbiZ1kRBUvqRJLmSNzfdMYxXaIk0r9EfxnUlEkpnuG73w6ugty7oNHQm44W3FWlPcRzEowzldMSHFG5lzKPClkmp3_yzOyiPGTMaFEkV2SmeCqKJlSc_K9bXrExFiHPtrgdUtj12AfrKEwtsPYIw01bUanPd1Zv7N7nRjs7R4NdRjRQ3Nwx9aAjgK2baToG-0BI3V2sDs9TNqjAxp0YZjcujsk1psRJkXop64bIcSJjVfkotZtxOvTXZL3p8ft-iXZvD2_rh82CciUD0lds5JBDqooAGTGeaYAa-QsywvUWkGZAue1kLkGhbmRpmZpmYNgRrISa7Ekd7_erg9fI8ahcjYex2uPYYxVqdKsTGVaTOTtiRw_HJqq663T_aH6-6D4AdebeOM
CitedBy_id	crossref_primary_10_1186_s13287_024_03694_4 crossref_primary_10_3390_cells11182792 crossref_primary_10_1186_s13287_023_03423_3 crossref_primary_10_1002_btm2_70020 crossref_primary_10_3390_jfb10040052 crossref_primary_10_1007_s00784_020_03491_2 crossref_primary_10_1016_j_biopha_2022_113211 crossref_primary_10_1111_jre_12577 crossref_primary_10_1002_biot_202000389 crossref_primary_10_1155_2016_9176357 crossref_primary_10_32604_biocell_2022_018442 crossref_primary_10_1016_j_jbiotec_2017_09_020 crossref_primary_10_3390_cells8121620 crossref_primary_10_3389_fphys_2021_656588 crossref_primary_10_1002_art_37894 crossref_primary_10_1155_2020_8864572 crossref_primary_10_1007_s00441_016_2405_y crossref_primary_10_3390_bioengineering4020047 crossref_primary_10_1371_journal_pone_0225485 crossref_primary_10_1177_0394632017740976 crossref_primary_10_3390_cells12010178 crossref_primary_10_1186_s13287_021_02642_w crossref_primary_10_1186_s13287_017_0558_6 crossref_primary_10_1093_bbb_zbaf094 crossref_primary_10_1080_15548627_2020_1850608 crossref_primary_10_3390_cells11081313 crossref_primary_10_1038_s41598_019_42439_9 crossref_primary_10_1155_2021_8825332 crossref_primary_10_1007_s10006_025_01331_9 crossref_primary_10_3390_ijms22136831 crossref_primary_10_4252_wjsc_v15_i3_31 crossref_primary_10_2478_acb_2023_0001 crossref_primary_10_1016_j_joen_2017_03_016 crossref_primary_10_1371_journal_pone_0208291 crossref_primary_10_1007_s12015_020_10006_9 crossref_primary_10_1089_ten_tea_2015_0289 crossref_primary_10_1016_j_jobcr_2024_07_003 crossref_primary_10_1016_j_tice_2021_101538 crossref_primary_10_1155_2016_7154327 crossref_primary_10_1016_j_jcyt_2014_10_015 crossref_primary_10_1089_ten_teb_2018_0118 crossref_primary_10_1002_advs_201802104 crossref_primary_10_3390_ijms19020359 crossref_primary_10_3390_antiox9010066 crossref_primary_10_1016_j_biomaterials_2019_119573 crossref_primary_10_1155_2016_9062638 crossref_primary_10_3727_096368914X684051 crossref_primary_10_1007_s13233_016_4107_4 crossref_primary_10_1007_s12015_019_09886_3 crossref_primary_10_3389_fbioe_2020_00968 crossref_primary_10_1002_ijc_31619 crossref_primary_10_1002_stem_1909 crossref_primary_10_1016_j_patbio_2014_01_002 crossref_primary_10_1177_0022034518772260 crossref_primary_10_5966_sctm_2015_0111 crossref_primary_10_1177_0022034516657817 crossref_primary_10_1002_adhm_202001284 crossref_primary_10_1016_j_colsurfb_2021_112220 crossref_primary_10_1111_jcmm_17082 crossref_primary_10_1177_0022034512461016 crossref_primary_10_3390_ijms23031662 crossref_primary_10_1177_0022034518804531 crossref_primary_10_3389_fcell_2020_00473 crossref_primary_10_1016_j_ijpharm_2017_02_014 crossref_primary_10_1186_s13287_018_0804_6 crossref_primary_10_1016_j_jiec_2020_08_013 crossref_primary_10_1088_1758_5090_abd56c crossref_primary_10_1177_0022034514541124 crossref_primary_10_1002_adma_201500762 crossref_primary_10_1002_mba2_66 crossref_primary_10_1089_scd_2015_0278 crossref_primary_10_3390_app9040627 crossref_primary_10_1002_hed_23076 crossref_primary_10_3390_bioengineering5020048 crossref_primary_10_1186_s13287_021_02553_w crossref_primary_10_1002_btm2_10397 crossref_primary_10_3390_cells8040299 crossref_primary_10_1002_cre2_70151 crossref_primary_10_3390_mi11121066 crossref_primary_10_1371_journal_pone_0240833 crossref_primary_10_3390_bioengineering12090970 crossref_primary_10_1016_j_jconrel_2024_03_036 crossref_primary_10_1007_s00784_016_1867_3 crossref_primary_10_1007_s40496_014_0012_0 crossref_primary_10_1177_2041731420947242 crossref_primary_10_1007_s12010_019_03105_y crossref_primary_10_1186_s13075_016_1160_5 crossref_primary_10_1016_j_scr_2019_101536 crossref_primary_10_1155_2022_6544514 crossref_primary_10_1155_2019_9310318 crossref_primary_10_1016_j_cej_2025_160906 crossref_primary_10_3389_fimmu_2021_667221 crossref_primary_10_1007_s12035_024_03924_z crossref_primary_10_3892_etm_2018_6462 crossref_primary_10_1186_s13287_024_03659_7 crossref_primary_10_1088_1758_5090_ab21f6 crossref_primary_10_1111_odi_13224 crossref_primary_10_1016_j_bioadv_2025_214408 crossref_primary_10_1089_scd_2012_0401 crossref_primary_10_3390_cells9081916 crossref_primary_10_3390_cells10040719 crossref_primary_10_1186_s13287_016_0361_9 crossref_primary_10_1089_wound_2022_0037 crossref_primary_10_1016_j_sjbs_2022_02_039 crossref_primary_10_1002_btpr_1686 crossref_primary_10_1177_2041731417702531 crossref_primary_10_1016_j_jds_2016_03_010 crossref_primary_10_1155_2015_105135 crossref_primary_10_3892_etm_2017_4813 crossref_primary_10_1089_ten_tea_2014_0314 crossref_primary_10_1155_2017_4057612 crossref_primary_10_1186_1471_2164_15_10 crossref_primary_10_3390_ani13061043 crossref_primary_10_1016_j_ijbiomac_2023_123664 crossref_primary_10_1089_ten_teb_2023_0253 crossref_primary_10_3390_cells10082161 crossref_primary_10_1186_s13287_024_03934_7 crossref_primary_10_3389_fbioe_2021_621748 crossref_primary_10_1089_ten_tea_2016_0342 crossref_primary_10_3390_biomedicines11041049 crossref_primary_10_3390_app13148490 crossref_primary_10_1016_j_jconrel_2012_04_045 crossref_primary_10_1126_scitranslmed_aaw1120 crossref_primary_10_1002_jcp_25894 crossref_primary_10_1038_s41598_021_93642_6 crossref_primary_10_3389_fbioe_2021_611837 crossref_primary_10_1089_ten_teb_2013_0537
ContentType	Journal Article
Copyright	Mary Ann Liebert, Inc.
Copyright_xml	– notice: Mary Ann Liebert, Inc.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1089/scd.2011.0252
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Biology
EISSN	1557-8534
ExternalDocumentID	21689066
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCRR NIH HHS grantid: D41-RR01192 – fundername: NIDCR NIH HHS grantid: R01DE 019932 – fundername: NCI NIH HHS grantid: P30 CA062203 – fundername: NIDCR NIH HHS grantid: R01 DE019932
GroupedDBID	--- 0R~ 0VX 123 29Q 34G 39C 4.4 ABBKN ABJNI ACGFS ADBBV ADNWM AENEX ALMA_UNASSIGNED_HOLDINGS BNQNF CGR COF CS3 CUY CVF DU5 ECM EIF EJD F5P IHR IM4 MV1 NPM NQHIM O9- RML UE5 7X8 SCNPE
ID	FETCH-LOGICAL-c531t-ff090c7c688cc541146cefe10478eaa6c93c11f257ac6e7d5df0397c20d509ef2
IEDL.DBID	7X8
ISICitedReferencesCount	144
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000302222700011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1557-8534
IngestDate	Wed Oct 01 17:28:38 EDT 2025 Thu Jan 02 22:07:14 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Language	English
License	Mary Ann Liebert, Inc.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c531t-ff090c7c688cc541146cefe10478eaa6c93c11f257ac6e7d5df0397c20d509ef2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://escholarship.org/uc/item/58b59357
PMID	21689066
PQID	963493538
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_963493538 pubmed_primary_21689066
PublicationCentury	2000
PublicationDate	2012-04-10
PublicationDateYYYYMMDD	2012-04-10
PublicationDate_xml	– month: 04 year: 2012 text: 2012-04-10 day: 10
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Stem cells and development
PublicationTitleAlternate	Stem Cells Dev
PublicationYear	2012
References	21062632 - Life Sci. 2011 Jan 3;88(1-2):65-73 19841619 - Lab Invest. 2009 Dec;89(12):1410-22 20138833 - Biochem Biophys Res Commun. 2010 Mar 12;393(3):377-83 18192235 - Stem Cells. 2008 Apr;26(4):1047-55 20219413 - Oral Oncol. 2010 May;46(5):336-42 18253953 - Inflamm Bowel Dis. 2008 Jun;14(6):826-38 19783424 - Curr Opin Biotechnol. 2009 Oct;20(5):531-6 18708365 - Mol Cancer Res. 2008 Aug;6(8):1337-46 20869949 - Biochem Biophys Res Commun. 2010 Oct 29;401(4):509-15 19923445 - J Immunol. 2009 Dec 15;183(12):7787-98 19047138 - Cancer Res. 2008 Dec 1;68(23):9614-23 21451545 - J Invest Dermatol. 2011 Jul;131(7):1559-67 20857425 - J Cell Physiol. 2011 Mar;226(3):832-42 17761754 - Stem Cells. 2007 Dec;25(12):3143-54 18487568 - J Clin Oncol. 2008 May 20;26(15):2489-96 17467179 - Burns. 2007 Jun;33(4):418-28 19584147 - Clin Cancer Res. 2009 Jul 15;15(14):4641-8 20597105 - Stem Cells. 2010 Aug;28(8):1446-55 20109207 - BMC Cell Biol. 2010;11:11 20682444 - Cell Stem Cell. 2010 Aug 6;7(2):150-61 20412029 - Tissue Eng Part A. 2010 Sep;16(9):2891-9 19259334 - J Oncol. 2008;2008:907892 17241424 - Oral Dis. 2007 Jan;13(1):11-6 21262528 - Biomaterials. 2011 Apr;32(11):2734-47 18063840 - Am J Respir Crit Care Med. 2008 Apr 1;177(7):701-11 21280155 - Stem Cells. 2011 Jan;29(1):11-9 19215979 - Biomaterials. 2009 May;30(14):2705-15 19967788 - Stem Cells. 2010 Mar 31;28(3):585-96 20952688 - Blood. 2011 Jan 13;117(2):459-69 20879854 - Stem Cells Dev. 2011 May;20(5):915-23 10102814 - Science. 1999 Apr 2;284(5411):143-7 20882531 - Stem Cells. 2010 Nov;28(11):2088-98 20734355 - Stem Cells. 2010 Oct;28(10):1856-68 19698058 - Tissue Eng Part B Rev. 2010 Apr;16(2):159-68 19556498 - Science. 2009 Jun 26;324(5935):1666-9 20643923 - Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13724-9 20861473 - Am J Physiol Cell Physiol. 2010 Dec;299(6):C1562-70 19179402 - Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2331-6 15591043 - J Biol Chem. 2005 Mar 4;280(9):8094-100 19407239 - Circ Res. 2009 May 22;104(10):1209-16 15057287 - Nat Rev Cancer. 2004 Apr;4(4):277-84 20887949 - Cell Stem Cell. 2010 Oct 8;7(4):431-42 10388137 - Oncologist. 1998;3(6):446-451 16684817 - J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13 16700732 - Oral Dis. 2006 May;12(3):229-41 17925003 - Aging Cell. 2007 Dec;6(6):745-57 17521616 - Biochem Biophys Res Commun. 2007 Jul 6;358(3):948-53 15319267 - Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2021-7
References_xml	– reference: 18487568 - J Clin Oncol. 2008 May 20;26(15):2489-96 – reference: 19923445 - J Immunol. 2009 Dec 15;183(12):7787-98 – reference: 17521616 - Biochem Biophys Res Commun. 2007 Jul 6;358(3):948-53 – reference: 15591043 - J Biol Chem. 2005 Mar 4;280(9):8094-100 – reference: 16700732 - Oral Dis. 2006 May;12(3):229-41 – reference: 10388137 - Oncologist. 1998;3(6):446-451 – reference: 19967788 - Stem Cells. 2010 Mar 31;28(3):585-96 – reference: 18192235 - Stem Cells. 2008 Apr;26(4):1047-55 – reference: 20879854 - Stem Cells Dev. 2011 May;20(5):915-23 – reference: 17925003 - Aging Cell. 2007 Dec;6(6):745-57 – reference: 18708365 - Mol Cancer Res. 2008 Aug;6(8):1337-46 – reference: 19783424 - Curr Opin Biotechnol. 2009 Oct;20(5):531-6 – reference: 16684817 - J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13 – reference: 15319267 - Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2021-7 – reference: 19259334 - J Oncol. 2008;2008:907892 – reference: 10102814 - Science. 1999 Apr 2;284(5411):143-7 – reference: 20882531 - Stem Cells. 2010 Nov;28(11):2088-98 – reference: 19584147 - Clin Cancer Res. 2009 Jul 15;15(14):4641-8 – reference: 17241424 - Oral Dis. 2007 Jan;13(1):11-6 – reference: 20682444 - Cell Stem Cell. 2010 Aug 6;7(2):150-61 – reference: 21451545 - J Invest Dermatol. 2011 Jul;131(7):1559-67 – reference: 19179402 - Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2331-6 – reference: 21062632 - Life Sci. 2011 Jan 3;88(1-2):65-73 – reference: 20734355 - Stem Cells. 2010 Oct;28(10):1856-68 – reference: 19556498 - Science. 2009 Jun 26;324(5935):1666-9 – reference: 20109207 - BMC Cell Biol. 2010;11:11 – reference: 17761754 - Stem Cells. 2007 Dec;25(12):3143-54 – reference: 17467179 - Burns. 2007 Jun;33(4):418-28 – reference: 19047138 - Cancer Res. 2008 Dec 1;68(23):9614-23 – reference: 19841619 - Lab Invest. 2009 Dec;89(12):1410-22 – reference: 20643923 - Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13724-9 – reference: 20597105 - Stem Cells. 2010 Aug;28(8):1446-55 – reference: 18253953 - Inflamm Bowel Dis. 2008 Jun;14(6):826-38 – reference: 19215979 - Biomaterials. 2009 May;30(14):2705-15 – reference: 20857425 - J Cell Physiol. 2011 Mar;226(3):832-42 – reference: 20412029 - Tissue Eng Part A. 2010 Sep;16(9):2891-9 – reference: 15057287 - Nat Rev Cancer. 2004 Apr;4(4):277-84 – reference: 20952688 - Blood. 2011 Jan 13;117(2):459-69 – reference: 20869949 - Biochem Biophys Res Commun. 2010 Oct 29;401(4):509-15 – reference: 19698058 - Tissue Eng Part B Rev. 2010 Apr;16(2):159-68 – reference: 18063840 - Am J Respir Crit Care Med. 2008 Apr 1;177(7):701-11 – reference: 20138833 - Biochem Biophys Res Commun. 2010 Mar 12;393(3):377-83 – reference: 20887949 - Cell Stem Cell. 2010 Oct 8;7(4):431-42 – reference: 19407239 - Circ Res. 2009 May 22;104(10):1209-16 – reference: 21280155 - Stem Cells. 2011 Jan;29(1):11-9 – reference: 21262528 - Biomaterials. 2011 Apr;32(11):2734-47 – reference: 20219413 - Oral Oncol. 2010 May;46(5):336-42 – reference: 20861473 - Am J Physiol Cell Physiol. 2010 Dec;299(6):C1562-70
SSID	ssj0026284
Score	2.4241061
Snippet	Mesenchymal stem cells (MSCs) are capable of regenerative and immunomodulatory functions in cell-based therapies in a variety of human diseases and injuries;...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	937
SubjectTerms	Animals Cell Culture Techniques Drug-Related Side Effects and Adverse Reactions Gingiva - pathology Mesenchymal Stem Cell Transplantation Mesenchymal Stromal Cells - cytology Mice Spheroids, Cellular - pathology Stomatitis - pathology Stomatitis - prevention & control Stomatitis - therapy Treatment Outcome
Title	Three-dimensional spheroid culture of human gingiva-derived mesenchymal stem cells enhances mitigation of chemotherapy-induced oral mucositis
URI	https://www.ncbi.nlm.nih.gov/pubmed/21689066 https://www.proquest.com/docview/963493538
Volume	21
WOSCitedRecordID	wos000302222700011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV27TsMwFLWAgsTC-1Fe8sBq1YmdhyeEEBULVYcidatSX1vtkARIqdSP4J-5N0m7IQaWbI5i-_j6xL73HMbup0qDdBAISEMtdKKsMBGAiBUVdhptIPa12UQyGKTjsRm2uTlVm1a5jol1oIbS0hl5D4GijcLl-fD-Icg0ii5XWweNbdZRyGQI1Ml4c4kQxmFtOIw7JgbiSOlWYlOmpldZaOU7Qyo5-o1c1ptM__Cfn3fEDlp2yR8bOByzLVecsL3Gb3J1yr5HOHNOACn6N2ocvCJZgXIOvJHgcLz0vPbt4-ReNF9mAhCjSwc8pzolO1vl1Grhck5n_hV3xYyAU_F83sh1lAW9A7GQt8VdK4H__Ygg4KQGwHPKkSclpTP21n8ePb2I1o9BWFypC-G9NNImNk5TayNN9czWeVcL_Lgsi61RNgg8BoHMxi6BCLxEumNDCUhLnA_P2U5RFu6ScY0gQOIgE2yvEcxGgcVoovw08BnIaZfx9TBPEO_Uoaxw5Vc12Qx0l100UzV5b3Q5JmEQpwYp1NXfja_ZPk5_SNdCgbxhHY9r3d2yXbvE7n_e1TjC52D4-gNKg9dS
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Three-dimensional+spheroid+culture+of+human+gingiva-derived+mesenchymal+stem+cells+enhances+mitigation+of+chemotherapy-induced+oral+mucositis&rft.jtitle=Stem+cells+and+development&rft.au=Zhang%2C+Qunzhou&rft.au=Nguyen%2C+Andrew+L&rft.au=Shi%2C+Shihong&rft.au=Hill%2C+Colin&rft.date=2012-04-10&rft.issn=1557-8534&rft.eissn=1557-8534&rft.volume=21&rft.issue=6&rft.spage=937&rft_id=info:doi/10.1089%2Fscd.2011.0252&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-8534&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-8534&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-8534&client=summon